Chronic carriers of Hepatitis B virus (HBV) infection, who are treated for malignant lymphoma, are at high risk of mortality from reactivated HBV infection. We report a case of a 29-yearold male chronic HBV carrier who developed fulminant reactivated HBV infection following intensive chemotherapy for stage IV B large cell B-cell non-Hodgkin's lymphoma associated with extensive central nervous system and bone marrow involvement. Prior to chemotherapy the patient had normal liver function tests and was negative for HBV DNA by semiquantitative PCR assay. Fulminant HBV reactivation was confirmed following clinical deterioration, massive rises in hepatic transaminases (peak alanine aminotransferase = 2,850 U/l), liver biopsy and rising levels of serum HBV DNA. Following treatment with lamivudine 150 mg bd for 18 weeks dramatic and sustained recovery ensued. Symptoms and liver function tests improved within days and HBV DNA became negative within 12 weeks. Our patient later died from relapsed lymphoma but without evidence of reactivated HBV infection. We advise that lamivudine should be considered during intensive chemotherapy treatment of chronic carriers of HBV.
Introduction
A recent article in this journal has highlighted the high frequency and mortality associated with the development of reactivated hepatitis B virus (HBV) infection in carriers of HBV infection treated for malignant lymphoma [l] .We report a case of reactivated fulminant hepatitis B, which developed in a chronic HBV carrier following intensive chemotherapy for advanced stage aggressive B-cell non-Hodgkins lymphoma (NHL) and which responded dramatically to therapy with the antiretroviral agent lamivudine.
Case report
A 29-year-old male chronic HBV carrier presented with features consistent with stage IV B large cell B-cell NHL with extensive central nervous system and bone marrow involvement. Diagnostic tissue was obtained from a CT guided biopsy of the sacrum which showed large cells expressing CD19 and IgA. with a high percentage of cells staining for the proliferation marker JCi67. Radiological investigations revealed compression fractures of C5 and T2, with an adjacent soft tissue mass at the level of C5, multiple destructive bony lesions in the pelvis and sacrum and associated soft tissue masses, and a lytic lesion in the proximal left femur. MRI scan of the head showed a large left-sided intracranial mass with midline shift, oedema and destruction of overlying bone with an adjacent soft tissue mass. A bone marrow trephine showed extensive focal areas of lymphomatous infiltration but marrow aspirate analysis for morphological evidence of lymphoma, cytogenetics and /x7-2/IgH and IgH gene rearrangements was normal. Molecular analysis of sacral tissue showed an oligoclonal pattern for IgH rearrangements. The presentation LDH was 1410 U/l (NR 230-460 U/l), IgG showed a polyclonal increase and renal function was normal.
He was known to be a chronic HBV carrier for eight years, believed related to either i.v. drug abuse or heterosexual contact. There had been no history of an acute hepatitis illness. At presentation liver function was normal and he was hepatitis B surface antigen (HBsAg) positive, e antigen (HBeAg) negative and e antibody (anti-HBe) positive. Hepatitis B DNA (HBV DNA) was negative. He was seronegative for HIV, HCVand TPHA.
He was treated initially with dexamethasone and radiotherapy to the cranium of 10 Gy in five fractions, before commencing the United Kingdom Childhood Cancer Study Group protocol for aggressive B-cell lymphomas with both bone marrow and central nervous system involvement [2] . He received initial COP (cyclophosphamide, vincristine and prednisone) followed by five cycles of intensive chemotherapy including intrathecal methotrexate, prednisone, cyclophosphamide, doxorubicin, vincristine, etoposide and high-dose cytarabine. He received further craniocervical radiotherapy, 24 Gy in 12 fractions and on completion of this treatment was shown to be in complete remission. Towards the end of this treatment and prior to commencing cranial radiotherapy, a gradual progressive rise in hepatic transaminases was noted with peak values of AST 1870 U/l, ALT 2850 U/l, gamma GT 380 U/l and bilirubin 298 umol/1 (Figure 1 ). His prothrombin ratio was prolonged at 1.7. Repeat testing for hepatitis B DNA was now positive by nested nucleic acid amplification, a semi-quantitative test showing a high level of HBV DNA. He remained negative for hepatitis B e antigen and a liver biopsy showed a mild hepatitis with strong positive staining of hepatocyte cytoplasm for HBsAg and strong positive staining of hepatocyte nuclei for HBcAg.
He was then commenced on lamivudine, 150 mg twice daily and received supportive care and vitamin K. Over the following days his liver function tests and symptoms progressively improved. This was sustained over subsequent weeks becoming near normal after ten weeks of lamivudine therapy (Figure 1 ). Repeat HBV DNA testing six weeks from the start of treatment showed a low but persistent level of HBV DNA and 12 weeks into treatment with lamivudine his HBV DNA result became negative. After a further six weeks therapy and repeat negative results for HBV DNA lamivudine was discontinued.
The final three cycles, comprising less intensive chemotherapy, were omitted in order to avoid further immunosuppression and the patient remained off treatment. Six months from the acute reactivation of HBV infection the patient remained well with normal liver function tests and negative testing for HBV DNA. He continued in clinical remission with extensive restaging investigations having shown no evidence of lymphoma. Six weeks later, however, he presented with relapsed lymphoma with bone involvement. This progressed rapidly despite palliative radiotherapy and he died shortly afterwards. His liver function tests remained normal, apart from a pre-terminal rise in alkaline phosphatase, as did repeat testing for HBV DNA.
Discussion
Since 1975 it has been noted that the profound immunosuppression of cytotoxic chemotherapy in hepatitis B surface antigen (HBsAg) carriers can result in acute hepatitis and fulminant hepatic failure, particularly when chemotherapy is withdrawn [3] [4] [5] . Given that there are upwards of 300 million carriers worldwide it is a not uncommon problem in malignancy and its treatment. In a recent large epidemiological study of HBsAg carriers treated for malignant lymphoma 37.8% developed hepatitis and 41.2% of those affected died of hepatic failure following cessation of cytotoxic treatment [1] . Hepatitis and fulminant liver failure were significantly more common in patients treated with more intensive regimens and in patients who had seroconverted (HBeantigen negative and anti-HBe-antibody positive), possibly due to the presence of mutated HBV. Our patient showed evidence of pre-core mutant infection as he was positive for HBV DNA and negative for HBeAg. It is thought that hepatitis B virus (HBV) replication occurs during the period of immunosuppression, with hepatitis also developing on recovery of the host immune system. The high mortality clearly indicates that this is a most serious complication of chemotherapy.
To date, treatment has included supportive care only, corticosteroids, plasma exchange, and interferon-a and -(3 [6] . There has been little success with these methods although some success with interferon (with its known capacity to inhibit HBV replication) has led some authors to recommend concomitant interferon treatment with chemotherapy [1] . We now report a case in which lamivudine was used as treatment, with clinical, biochemical and virological resolution of acute HBV hepatitis. Lamivudine is an oral nucleoside analogue that has potent inhibitory effects on HBV in vitro and in vivo. As well as suppressing HBV DNA in HBsAg carriers [7] it has also been shown to improve liver histology [8] . Our patient's clinical course demonstrates that he was at high-risk of hepatic failure and we believe lamivudine played a significant role in his recovery. Furthermore, a recent study suggests synergism in vitro, when lamivudine is used in combination with penciclovir [8] and it may be useful, therefore, to use lamivudine in combination with famciclovir, the oral pro-drug of penciclovir, in this setting. It is also possible such a combination may be more effective as prophylaxis. Lamivudine is well tolerated and suited to long term exposure. It demonstrates low cytotoxicity to a variety of bone marrow progenitor cells in vitro and extensive clinical experience has demonstrated that long term exposure is well tolerated in HIV patients, including those concurrently treated with zidovudine [10] . We would advise, therefore, that lamivudine ± famciclovir should be considered during intensive chemotherapy treatment of chronic carriers of HBV. We suspect that such treatment is likely to reduce the risk of severe hepatitis and fulminant hepatic failure in these patients.
